<DOC>
	<DOCNO>NCT01371825</DOCNO>
	<brief_summary>This open-label , repeat-dose , intra-subject dose escalation study SBC-102 ( USAN : sebelipase alfa ) child growth failure due LAL Deficiency . Eligible subject receive once-weekly ( qw ) infusion sebelipase alfa 5 year</brief_summary>
	<brief_title>SurVival Lysosomal Acid Lipase Deficiency ( LAL-D ) Infants Treated With SebelipAse aLfa</brief_title>
	<detailed_description>Lysosomal Acid Lipase ( LAL ) Deficiency rare autosomal recessive lipid storage disorder cause marked decrease almost complete absence LAL , lead accumulation lipid , predominately cholesteryl ester triglyceride , various tissue cell type . In liver , accumulation lipid lead hepatomegaly , liver dysfunction , hepatic failure . Although single disease , LAL Deficiency present clinical continuum two major phenotype , Cholesteryl Ester Storage Disease ( CESD ) Wolman Disease . Early Onset LAL Deficiency ( Wolman Disease ) extremely rare , estimate incidence less 2 life per million . It characterize profound malabsorption , growth failure , hepatic failure , usually fatal first year life . There currently approve therapy treatment LAL Deficiency .</detailed_description>
	<mesh_term>Wolman Disease</mesh_term>
	<criteria>Subject 's parent legal guardian provide write informed consent/permission prior study procedure . Male female child document decreased LAL activity relative normal range lab perform assay document result molecular genetic testing ( 2 mutation ) confirm diagnosis . Growth failure onset 6 month age . Clinically important concurrent disease . Has receive investigational product sebelipase alfa within 14 day prior first dose . Subject old 24 month age . Myeloablative preparation , systemic pretransplant conditioning , hematopoietic stem cell liver transplant . Previous hematopoietic stem cell liver transplant . Known hypersensitivity egg .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>LIPA</keyword>
	<keyword>Wolman Disease</keyword>
	<keyword>Wolman Phenotype</keyword>
	<keyword>Acid Lipase Deficiency</keyword>
	<keyword>Acid Cholesteryl Hydrolase</keyword>
	<keyword>Acid Lipase Disease Deficiency , type 2</keyword>
	<keyword>Cholesteryl Ester Storage Disease ( CESD )</keyword>
	<keyword>Cholesteryl Ester Hydrolase Deficiency</keyword>
	<keyword>Early Onset Lysosomal Acid Lipase Deficiency ( Wolman Disease )</keyword>
	<keyword>LAL Deficiency</keyword>
	<keyword>Late Onset Lysosomal Acid Lipase Deficiency ( CESD )</keyword>
	<keyword>Wolman Disease ( early onset LAL Deficiency )</keyword>
	<keyword>Related Disorders :</keyword>
	<keyword>Non-alcoholic Fatty Liver Disease ( NAFLD )</keyword>
	<keyword>Non-alcoholic Steatohepatitis ( NASH )</keyword>
	<keyword>Alcoholic Liver Disease</keyword>
	<keyword>Cryptogenic Cirrhosis</keyword>
	<keyword>Niemann-Pick Disease ( NPD ) Type C</keyword>
	<keyword>Chanarin Dorfman Syndrome</keyword>
</DOC>